Aurinia Pharmaceuticals Inc. closed its $28.8 million bought-deal offering, which included $3.8 million pursuant to an exercise of the underwriter's overallotment option, for the sale of 12,777,775 units at $2.25 per unit.

Each unit consists of one common share and one-half of one common share purchase warrant. Each warrant will be exercisable into one share for $3 apiece for a period of 5 years after the offering closes.

H.C. Wainwright & Co. LLC was sole book-running manager and Cormark Securities Inc. was co-manager for the offering.